These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38279391)

  • 1. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study.
    Northcott M; Gearing LJ; Nim HT; Nataraja C; Hertzog P; Jones SA; Morand EF
    Lancet Rheumatol; 2021 May; 3(5):e357-e370. PubMed ID: 38279391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
    Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent Tuberculosis Infection and Associated Factors in Patients with Systemic Lupus Erythematosus: a Multicenter, Cross-Sectional Study.
    Zhang L; Ma Y; Jiang N; Zou X; Zhang Y; Zhang F; Zeng X; Zhao Y; Liu S; Zuo X; Wu H; Wu L; Li H; Zhang Z; Chen S; Zhu P; Zhang M; Qi W; Liu Y; Liu H; Shi X; Liu X
    Microbiol Spectr; 2023 Jun; 11(3):e0084823. PubMed ID: 37158726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus.
    Siddiqi KZ; Zinglersen AH; Iversen KK; Rasmussen NS; Nielsen CT; Jacobsen S
    J Autoimmun; 2022 Oct; 132():102869. PubMed ID: 35933792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway.
    Spies CM; Schaumann DH; Berki T; Mayer K; Jakstadt M; Huscher D; Wunder C; Burmester GR; Radbruch A; Lauster R; Scheffold A; Buttgereit F
    Ann Rheum Dis; 2006 Sep; 65(9):1139-46. PubMed ID: 16449313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A cross-sectional study on application of glucocorticoid in systemic lupus erythematosus patients].
    Xu LL; Guo QY; Cai XY; Da ZY; Zhu HQ; Zhang LY; Su Y
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):290-294. PubMed ID: 28355723
    [No Abstract]   [Full Text] [Related]  

  • 8. IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.
    Rodríguez-Carrio J; López P; Alperi-López M; Caminal-Montero L; Ballina-García FJ; Suárez A
    Front Immunol; 2018; 9():3085. PubMed ID: 30666255
    [No Abstract]   [Full Text] [Related]  

  • 9. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
    Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
    Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.
    Braunstein I; Klein R; Okawa J; Werth VP
    Br J Dermatol; 2012 May; 166(5):971-5. PubMed ID: 22242767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant GITR expression on different T cell subsets and the regulation by glucocorticoid in systemic lupus erythematosus.
    Sun J; Yu N; Li X; Wang L; Pan Y; Li X; Tao J; Chen Z; Wang G
    Int J Rheum Dis; 2016 Feb; 19(2):199-204. PubMed ID: 25293713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature.
    Arnaud L; Furie R; Morand EF; Aringer M; Peschken C; Desta B; Rapsomaniki E; Hedberg J; Knagenhjelm J; Seo C; Grünfeld Eén T; Sorrentino A; Tummala R; Stirnadel-Farrant HA; Ding B
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38123459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome.
    van den Hoogen LL; van Roon JAG; Mertens JS; Wienke J; Lopes AP; de Jager W; Rossato M; Pandit A; Wichers CGK; van Wijk F; Fritsch-Stork RDE; Radstake TRDJ
    Ann Rheum Dis; 2018 Dec; 77(12):1810-1814. PubMed ID: 30185417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis.
    Northcott M; Jones S; Koelmeyer R; Bonin J; Vincent F; Kandane-Rathnayake R; Hoi A; Morand E
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35197305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus.
    Du J; Li M; Zhang D; Zhu X; Zhang W; Gu W; Feng Y; Zhai X; Ling C
    Arthritis Res Ther; 2009; 11(4):R108. PubMed ID: 19594946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ).
    Dankers W; Northcott M; Bennett T; D'Cruz A; Sherlock R; Gearing LJ; Hertzog P; Russ B; Miceli I; Scheer S; Fujishiro M; Hayakawa K; Ikeda K; Morand EF; Jones SA
    Front Immunol; 2022; 13():1034880. PubMed ID: 36505447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.
    Miyawaki Y; Shimizu S; Ogawa Y; Sada KE; Katayama Y; Asano Y; Hayashi K; Yamamura Y; Hiramatsu-Asano S; Ohashi K; Morishita M; Watanabe H; Takano-Narazaki M; Matsumoto Y; Yajima N; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M; Yamazaki H; Yamamoto Y; Wada J; Fukuhara S
    Arthritis Res Ther; 2021 Mar; 23(1):79. PubMed ID: 33691746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus.
    Petri M; Fu W; Ranger A; Allaire N; Cullen P; Magder LS; Zhang Y
    BMC Med Genomics; 2019 Jan; 12(1):4. PubMed ID: 30626389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.